Bryant Furlow

Bryant Furlow is medical journalist working at the crossroads of research, clinical practice, and public policy. His work has appeared the Lancet, New Scientist, and Oncology Nurse Advisor.

Most Recent Articles by Bryant Furlow

Lung Cancer Immunotherapy in Elderly Patients: Cause for Optimism?

Lung Cancer Immunotherapy in Elderly Patients: Cause for Optimism?

By

Targeted and immunotherapies appear to be opening a new frontier in the management of elderly patients.

Improvement Needed in CML BCR-ABL1 Monitoring

Improvement Needed in CML BCR-ABL1 Monitoring

By

Technical standardization and development of the International Scale for reporting Philadelphia chromosome BCR-ABL1 fusion gene expression has improved consistency.

Breast Cancer Subtype and Brain Metastasis Risk at Diagnosis

Breast Cancer Subtype and Brain Metastasis Risk at Diagnosis

By

Breast cancer subtype influences the probability that a patient has brain metastases at the time of diagnosis.

Non-invasive Biomarkers for Metastatic Prostate Cancer

Non-invasive Biomarkers for Metastatic Prostate Cancer

By

Can liquid biopsy and molecular imaging biomarkers help inform more precise management of patients with metastatic prostate cancer?

Industry Payments Influence Research, Prescribing, and Advocacy

Industry Payments Influence Research, Prescribing, and Advocacy

By

Clinical trial investigators who receive drug industry funding are about 3.5 times as likely to find positive results as trials led by scientists who did not receive industry payments.

More Articles by Bryant Furlow

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters